CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0
CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Submission of Matters to a Vote of Security Holders

CYTRX CORPORATION (NASDAQ:CYTR) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07Submission of Matters to a Vote of Security Holders

Proposal S1: the stockholder proposal regarding "Barring Officers and Employees From Board Service" was not approved based upon the following votes:

For

Against

Abstain

Broker Non-Votes

4,129,896

5,180,167

51,436

16,313,728

44.12%

55.88%

0.55%

Proposal S2: the stockholder proposal regarding "Amend Charter to Terminate CEO Upon Felony Conviction" was not approved based upon the following votes:

For

Against

Abstain

Broker Non-Votes

4,454,335

4,859,085

48,352

16,313,728

47.58%

52.42%

0.52%

Proposal S3: the stockholder proposal regarding "Pricing of Stock, Options and Warrants" was not approved based upon the following votes:

For

Against

Abstain

Broker Non-Votes

3,970,421

3,272,130

2,114,721

16,313,728

42.43%

57.57% **

22.60%

** In accordance with the Company's voting standards, abstentions are added to the tally of "Against" votes, since the shares underlying an abstention are counted as present at the Annual Meeting.

Proposal S4: the stockholder proposal regarding "Indemnification of Officers" was not approved based upon the following votes:

For

Against

Abstain

Broker Non-Votes

3,821,241

3,370,788

2,169,743

16,313,728

40.82%

59.18% **

23.18%

** In accordance with the Company's voting standards, abstentions are added to the tally of "Against" votes, since the shares underlying an abstention are counted as present at the Annual Meeting.


About CYTRX CORPORATION (NASDAQ:CYTR)

CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The Company is focused on the clinical development of aldoxorubicin, its modified version of the chemotherapeutic agent, doxorubicin. It is engaged in Phase III trials for aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed after treatment with chemotherapy. It is also involved in evaluating aldoxorubicin in a Phase IIb clinical trial in small cell lung cancer; a Phase II clinical trial in human immunodeficiency virus-related Kaposi’s sarcoma; a Phase II clinical trial in patients with late-stage glioblastoma (brain cancer); a Phase Ib trial in combination with ifosfamide in patients with STS, and a Phase Ib trial in combination with gemcitabine in subjects with metastatic solid tumors. It is engaged in the pre-clinical development for DK049, an anti-cancer drug conjugate that utilizes its Linker Activated Drug Release (LADR) technology.